Synaptic vesicles in the nerve terminal play a pivotal role in neurotransmission. Neurotransmitter accumulation into synaptic vesicles is catalyzed by distinct vesicular transporters, harnessing an electrochemical proton gradient generated by V-type proton-pump ATPase. However, little is known about regulation of the transmitter pool size, particularly in regard to amino acid neurotransmitters. We previously provided evidence for the existence of a potent endogenous inhibitory protein factor (IPF), which causes reduction of glutamate and GABA accumulation into isolated, puri®ed synaptic vesicles. In this study we demonstrate that IPF is concentrated most in the synaptosomal cytosol fraction and that, when introduced into the synaptosome, it leads to a decrease in calcium-dependent exocytotic (but not calcium-independent) release of glutamate in a concentration-dependent manner. In contrast, a-fodrin (nonerythroid spectrin), which is structurally related to IPF and thought to serve as the precursor for IPF, is devoid of such inhibitory activity. Intrasynaptosomal IPF also caused reduction in exocytotic release of GABA and the monoamine neurotransmitter serotonin. Whether IPF affects vesicular storage of multiple neurotransmitters in vivo would depend upon the localization of IPF. These results raise the possibility that IPF may modulate synaptic transmission by acting as a quantal size regulator of one or more neurotransmitters.
It is now widely accepted that glutamate functions as the major excitatory neurotransmitter in the vertebrate central nervous system (Fonnum 1984; Collingridge and Bliss 1987; Cotman et al. 1987; Watkins et al. 1990 ). As such, proper glutamate transmission is required for learning and memory formation (Collingridge and Bliss 1987; Cotman et al. 1988; Zalutsky and Nicoll 1990; Malgaroli and Tsien 1992; Bliss and Collingridge 1993) . Aberrant glutamate transmission has been implicated in a variety of neurological and psychiatric disorders, including epilepsy, ischemiainduced neuronal cell death, Huntington's chorea, Alzheimer's disease and schizophrenia (Choi and Rothman 1990; Meldrum 1991; Coyle and Puttfarcken 1993; Bradford 1995; Bunney et al. 1995; Chapman 1998; Moghaddam and Adams 1998) . Glutamate transmission is postsynaptically mediated by various, distinct types of receptors, namely, AMPA, kainate and NMDA receptor/channels, and metabotropic receptors coupled to phosphatidyl inositol bisphosphate lipase C and adenylate cyclase (Sladeczek et al. 1988; Monaghan et al. 1989; Watkins et al. 1990; Nakanishi 1992; Hollmann and Heinemann 1994) .
Presynaptically, despite the past controversy, evidence has now accumulated to strongly support the concept that synaptic vesicles play a pivotal role in glutamate synaptic transmission (Ueda 1986; Nicholls 1989; Maycox et al. 1990 ; O È zkan and Ueda 1998). Both highly speci®c, ATP-dependent, glutamate accumulation into isolated synaptic vesicles (Naito and Ueda 1983; Naito and Ueda 1985; Maycox et al. 1988; Cidon and Sihra 1989; Fykse et al. 1989; Tabb et al. 1992; Moriyama and Yamamoto 1995) and enrichment of glutamate in the synaptic vesicles (Storm-Mathisen et al. 1983; Burger et al. 1989 ) have been demonstrated. A variety of evidence indicates that glutamate is taken up into synaptic vesicles via a mechanism coupled to the electrochemical proton gradient Dm H
1
. This gradient is composed of the membrane potential (Dc) and the transmembrane pH difference (DpH), generated by a vacuolar type of proton-pump ATPase in the synaptic vesicle membrane. Although the membrane potential alone can drive glutamate uptake (Maycox et al. 1988; Cidon and Sihra 1989; Tabb et al. 1992 ), both elements of Dm H 1 , namely membrane potential and pH gradient, are important for maximal uptake activity seen under physiologically relevant Cl 2 concentrations (Naito and Ueda 1985; Tabb et al. 1992; Wolosker et al. 1996; Bellocchio et al. 2000) . It has recently been demonstrated that BNPI, a brain-speci®c Na 1 -dependent inorganic phosphate transporter (Ni et al. 1994) functions as a vesicular glutamate transporter (Bellocchio et al. 2000; Takamori et al. 2000) . However, it has a rather restricted distribution in the brain and hence is thought to represent an isoform of the vesicular glutamate transporter (Bellocchio et al. 2000) . Nicholls and associates (Nicholls and Sihra 1986; McMahon and Nicholls 1991) ; Kish and Ueda (1991) ; Wilson and associates (Mehta et al. 1996) and Takamori et al. (2000) have provided evidence that glutamate is released from synaptic vesicles by an exocytotic mechanism.
Vesicular accumulation of glutamate thus plays a crucial role in directing the common biochemical glutamate toward the neurotransmitter pathway and diverting it away from the general metabolic pathway (Ueda 1986 ; O È zkan and Ueda 1998). Since branch points in biochemical pathways are often sites of regulation, we postulated that vesicular glutamate uptake may be subject to such regulation. In light of these considerations, we obtained evidence for the existence of a potent inhibitory protein (Lobur et al. 1990; O È zkan et al. 1997 ) that may serve as an endogenous modulator for this process. This protein, designated as inhibitory protein factor (IPF), inhibits ATP-dependent accumulation of not only glutamate but also GABA (g-aminobutyric acid), whereas it exhibits no inhibition of Na 1 -dependent glutamate uptake into synaptosomes (O È zkan et al. 1997 ). IPF appears to be derived from the a subunit of the cytoskeletal protein fodrin (non-erythroid or brain spectrin), by at least two steps of cleavage, generating the distinct N-terminal sequence YHRFKELSTLRRAKLED-SYR, although the alternative possibility is not entirely ruled out that it is synthesized de novo according to the nucleotide sequence of a speci®c`IPF mRNA'. In contrast to IPF, neither isolated fodrin nor its a subunit exhibits inhibitory activity. Although fodrin is known to occur in virtually all cells, contributing to the cytoskeletal structure (Goodman et al. 1995) , the cellular and subcellular localization of IPF, as well as its physiological function, remains to be elucidated. In this communication, we report evidence suggesting that IPF is associated with synaptic vesicles. Moreover, in an effort to demonstrate that IPF functions within the nerve terminal as a potential regulator of exocytotic release of glutamate (and possibly of other neurotransmitters as well), we have introduced isolated IPF into synaptosomes and examined its effect on subsequent, depolarization-induced Ca
21
-dependent release of glutamate, GABA and serotonin. We present evidence here that isolated IPF, when permeated into synaptosomes, leads to a decrease in exocytotic release of these neurotransmitters. Part of this work was previously presented in abstract form (Tamura et al. 1998) .
Materials and methods
Puri®cation of IPF and fodrin IPF was puri®ed by the method of O È zkan et al. (1997) . Two Mono Q-puri®ed fractions rich in IPFa and IPFbg, respectively, were used in the experiments described here. The latter preparation contained a mixture of IPFb and IPFg. Fodrin and its a subunit were puri®ed from bovine brain by the procedures described by Bennett et al. (1986) and Calvert et al. (1980) , respectively. 
Preparation of synaptosomes
Crude synaptosomes were prepared at 48C by a modi®cation of the method of Krueger et al. (1977) . Male Sprague-Dawley rats (190±200 g) were killed by decapitation. The brain was removed within 1 min after decapitation and hemisected. Cerebellum, brainstem and white matter were removed from each hemisphere. One and a half grams of cerebrum were homogenized in 10 mL of ice-cold 0.32 m sucrose in 4 mm Tris±HCl, pH 7.4 (sucrose solution), with 12 up-and-down strokes in a glass-Te¯on homogenizer. The homogenate was diluted with 5 mL of sucrose solution and centrifuged at 1000 g max for 10 min. The supernatant was removed with a pipette and the pellet rehomogenized in 10 mL of sucrose solution with 4 up-and-down strokes, and centrifuged at 1000 g max for 10 min. The supernatants were combined and centrifuged at 1000 g max for 10 min, and the pellet discarded. The supernatant was then centrifuged at 12 500 g max for 15 min; the pellet was washed by resuspending in 15 mL of sucrose solution and centrifuging at 12 500 g max for 15 min. The resulting pellet (P2) was used as the crude synaptosome preparation in all experiments described here. Protein was quanti®ed with the Coomassie Protein Assay Kit from Pierce (Rockford, IL, USA), with bovine serum albumin as standard.
Introduction of isolated IPF and fodrin into synaptosomes
Freshly prepared synaptosomes were frozen/thawed by a modi®ca-tion of the method of Nichols et al. (1989) Figs 1 and 2 , in which the synaptosome protein concentration was 4 times higher. Isolated IPF was added to the synaptosome suspension. In control experiments, 50 mL of solution A were added instead of IPF. In vehicle experiments, 50 mL of the medium (300 mm NaCl in 20 mm Tris±HCl buffer, pH 7.4), in which IPF had been dissolved, were added, instead of IPF. To each mixture, 117.5 mL of solution A were added, followed by addition of 7.5 mL of l-[G-3 H]glutamate (50 Ci/mmol, Amersham Pharmacia Biotech, Piscataway, NJ, USA) (7.5 mCi). The total volume of the mixture was 375 mL, to which 375 mL of 10% dimethylsulfoxide (DMSO) (Fisher Scienti®c, Pittsburgh, PA, USA) in solution A were added, rendering the ®nal concentration of DMSO 5%. The entire mixture (750 mL) was frozen for 3 min in an isopropyl alcohol/dry ice bath. The frozen samples were thawed at 1±48C with periodic agitation over 10 min. Permeabilization and resealing of synaptosomes were carried out in the presence of Mg-ATP and the low concentration of chloride (4 mm) as described above, allowing selective glutamate uptake into synaptic vesicles within the synaptosome during the subsequent incubation at 308C for 10 min. These conditions have been shown to give rise to maximal uptake of glutamate into isolated synaptic vesicles (Naito and Ueda 1985; Carlson et al. 1989; Fykse et al. 1989; Tabb et al. 1992; Hartinger and Jahn 1993; Wolosker et al. 1996; Bellocchio et al. 2000) . This procedure permitted us to selectively monitor exocytotic release with ease. At the end of the thawing period, the samples were rapidly diluted with 10 mL of oxygenated balanced salt solution (BSS); 116.4 mm NaCl; 5.4 mm KCl; 1.3 mm MgSO 4 ; 0.92 mm Na 2 HPO 4 ; 26.2 mm NaHCO 3 ; 11 mm glucose; 0.1 mm EGTA, pH 7.4) and centrifuged at 10 000 g max for 10 min. The pellets were suspended in 1.5 mL of BSS and incubated for 10 min at 308C. At the end of the incubation period, the extrasynaptosomal medium was removed by centrifugation at 10 000 g max for 10 min. The pelleted synaptosomes were washed twice by resuspending in 10 mL of BSS and centrifuging at 10 000 g max for 10 min. The washed synaptosome preparation was resuspended in 1.5 mL of oxygenated BSS. Isolated fodrin or a-fodrin was introduced into synaptosomes by the same method described above.
Assay for glutamate release [ 3 H]Glutamate-loaded, resealed and washed synaptosomes (in 1.5 mL of BSS) were preincubated at 308C for 1.5 min. Aliquots (150 mL) were mixed with 150 mL of the following preoxygenated release solutions at 308C (RS 1±4) and incubated at 308C for various periods of time as follows: RS 1: 116.4 mm NaCl, 5.4 mm KCl, 1.3 mm MgSO 4 , 0.92 mm Na 2 HPO 4 , 26.2 mm NaHCO 3 , 11 mm glucose, 0.1 mm EGTA, and 4 mm dl-threo-b-hydroxy aspartate (pH 7.4) RS 2: RS 1 plus 2.6 mm CaCl 2 RS 3: RS 1 plus 94.6 mm KCl minus 94.6 mm NaCl RS 4: RS 3 plus 2.6 mm CaCl 2 Release was stopped by placing the samples on ice, followed by centrifugation at 10 000 g max for 10 min at 48C. Radioactivity in the 250-mL aliquot of the supernatant was determined in a Beckman LS 6500 scintillation spectrophotometer.
Assay for GABA and serotonin release The assay conditions for GABA and serotonin release were the same described for the glutamate release assay, except that (a) [ Monitoring IPF and Fodrin contents in the synaptosome IPF and fodrin were incorporated into the synaptosome as described above, except for the omission of [ 3 H]glutamate. The IPF-or fodrincontaining synaptosomes described above were incubated for 10 min at 308C, followed by centrifuged at 10 000 g max for 10 min. The pellet was washed twice and resuspended in 1.5 mL of 6 mm Tris±maleate (pH 8.3) for 45 min to lyse synaptosomes, and centrifuged at 10 000 g max for 10 min. The resulting supernatant was concentrated by using a vacuum centrifuge (,5-fold), and subjected to sodium dodecyl sulfate (SDS)/6% polyacrylamide gel electrophoresis, followed by electrophoretic transfer onto the nitrocellulose membrane (BioRad, Hercules, CA, USA); the transfer buffer contained 20% methanol, 192 nm glycine, and 25 mm Tris±HCl, pH 8.3. Blots were incubated with polyclonal antibodies raised against the N-terminal decapeptide of IPF (YHRFKELSTL) or of a-fodrin (MPSGVKVLE) and were visualized by enhanced chemiluminescence (ECL), according to the manufacturer's instructions (Amersham Pharmacia Biotech). Chemiluminescent blots were exposed to Hyper®lm ECL for 10 min at room temperature. The primary polyclonal antibodies to the N-terminal decapeptides of IPF and a-fodrin were raised in rabbits (Research Genetics, Huntsville, AL, USA); the former was shown to selectively recognize IPF and a-fodrin in a freshly prepared brain homogenate, as well as to interact with puri®ed IPF and a-fodrin, as judged by Western blots probed with horseradish peroxidase (Amano et al. in preparation).
Subcellular fractionation
Subcellular fractions of rat brain were obtained by a modi®cation of the procedure described in detail for canine cerebral cortex (Ueda et al. 1979) . Brie¯y, ®ve forebrains from 150±200 g SpragueDawley rats were homogenized in 10 volumes of 0.32 m sucrose, 1 mm NaHCO 3 , 1 mm EDTA, 1 mm EGTA, 3 mm benzamidine, and 0.3 mm phenylmethylsulfonyl¯uoride (PMSF). Forebrains were dispersed by 10 strokes with a Dounce homogenizer (Thomas C270) rotating at 800 r.p.m. Differential centrifugation produced a nuclear and cell debris pellet (P1) (10 min, 1400 g ave ), a crude mitochondrial plus synaptosomal pellet (P2) (10 min, 13 800 g ave ), a microsomal pellet (P3) (60 min, 105 000 g ave ), and the ®nal perikaryon supernatant (S1). The P1 pellet was washed once with the homogenization buffer. The P2 pellet was suspended in a minimal volume of homogenization buffer and osmotically shocked by addition of 9 volumes of ice cold 6 mm Tris±maleate, pH 8.1, containing 0.3 mm PMSF. After 45 min on ice, the osmotically shocked P2 fraction was centrifuged (20 min, 32 800 g ave ) to yield a plasma membrane/mitochondrial/myelin pellet (P4) and a supernatant containing synaptic vesicles (SV) and synaptosomal cytosol (S2). Crude synaptic vesicles (SV) and synaptosomal cytosol (S2) were separated by centrifugation (60 min, 105 000 g ave ). The crude synaptic vesicle fraction (SV) was suspended in 0.32 m homogenization buffer and subjected to centrifugation (120 min, 64 700 g ave ) on a discontinuous sucrose gradient consisting of equal volumes of 0.4 m, 0.6 m, and 0.8 m sucrose. Following centrifugation, ®ve fractions were recovered and contained: the top 0.32 m sucrose sample layer and the 0.32 m/ 0.4 m sucrose interface (fraction A), 0.4 m sucrose layer and the 0.4 m/0.6 m sucrose interface (fraction B), 0.6 m sucrose layer and the 0.6/0.8 m sucrose interface (fraction C), 0.8 m sucrose layer (fraction D), and pelleted material at the bottom of the tube (fraction E). Each fraction A±D was diluted to 0.25 m sucrose and centrifuged (60 min, 105 000 g ave ) to pellet synaptic vesicles and membrane fragments. Resulting pellets were suspended in a minimal volume of homogenization buffer (0.32 m sucrose), assayed for protein content, and stored at 2808C. Fraction B had previously been shown to be rich in synaptic vesicles (Ueda et al. 1979) . The amount of protein in each fraction was determined by the Bradford method (Pierce Coomassie Protein Assay Reagent) using bovine serum albumin as protein standard.
Western blotting of subcellular fractions
Proteins in the subcellular fractions obtained above were separated by SDS polyacrylamide gel (6%) electrophoresis (Laemmli 1970) and electrophoretically transferred onto the 0.45 m nitrocellulose membrane (BioRad). The electrophoretic transfer buffer contained 15.6 mm Tris base, 120 mm glycine, and 0.1% SDS, pH 8.3. Electrophoretic transfer was conducted for 1 h at 100 V (constant voltage) in a BioRad mini trans-blot electrophoretic transfer cell. Nitrocellulose blots were blocked with 5% non-fat dried milk dissolved in TBS (20 mm Tris±HCl, 0.5 m NaCl, pH 8.3). Nitrocellulose blots were incubated with a primary antibody followed by an alkaline phosphase-conjugated goat antirabbit IgG antibody (Sigma). Unbound antiserum or alkaline phosphataseconjugated secondary antibody was removed by 3 sequential washes with TBS containing 0.1% Tween 20. IPF antisera were raised in rabbits by immunization with the synthetic decapeptide corresponding to the N-terminal sequence of IPF (O È zkan et al. 1997) . BCIP and NBT were utilized as the substrate mixture for detection of bound alkaline phosphatase-conjugated secondary antibody (BioRad).
Results
Synaptosomes retain exocytotic ability after brief freeze treatment in DMSO Synaptosomes, which had been frozen for 3 min in the presence of the cryoprotectant DMSO, followed by thawing at 1±48C, were tested for the ability to exocytose the neurotransmitter glutamate. Fig. 1 DMSO-untreated, unfrozen (`intact') synaptosomes (data not shown). In contrast, when synaptosomes were subjected to freeze/thaw treatment without DMSO, no K 1 -evoked, Fig. 3 Effect of IPF incorporated into synaptosomes on exocytotic glutamate release at various times. Incorporation into synaptosomes of Mono Q-puri®ed IPFa was allowed at a concentration of 126 nM, as described in Materials and methods. In control experiments, an identical volume of an IPF-free solution containing 300 mM NaCl, 1 mM EDTA, 0.2 mM phenylmethyl sulfonyl¯uoride (PMSF), and 20 mM Tris±HCl, pH 7.6 (vehicle solution) was used. Glutamate release was allowed to proceed at 308C for the various times indi- , and 126 (lane 3) nM or in its absence (lane 4), followed by washing as described in Materials and methods. Washed synaptosomes were incubated for 10 min at 308C and lysed; intrasynaptosomal IPF was monitored by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)/ECL, using IPF N-terminal decapeptide antibodies as the probe, as described in Materials and methods.
Ca
21 -dependent release of [ 3 H]glutamate was observed. These results indicate that the synaptosome can retain its primary functional property, namely, the ability to release a neurotransmitter (glutamate, in this case) in response to depolarization in the presence of Ca 21 , even when it is subjected to freeze/thaw treatment, so long as DMSO (e.g. 5%) is present during the freeze/thaw cycle. These observations are in agreement with those previously reported by Nichols et al. (1989) , indicating that synaptosomes are permeabilized and resealed by freeze/thaw treatment in the presence of DMSO.
Time course of glutamate release from permeabilized/ resealed synaptosomes Fig. 2 (Fig. 2b ).
IPF inhibits [
3 H] glutamate release from synaptosomes To investigate the effect of IPF on depolarization-induced Ca 21 -dependent release of glutamate, IPF was introduced into synaptosomes as described in Materials and methods. The amount of [ 3 H]glutamate released from IPFa-treated synaptosomes was about 65% smaller than that from control synaptosomes, at all incubation times tested (Fig. 3a) . Since IPFbg, a mixture of IPFb and IPFg presumably produced during IPF puri®cation, also inhibited [ 3 H] glutamate uptake into isolated synaptic vesicles with almost identical potency (O È zkan et al. 1997 ; also in this study), we have examined the effect of introduction of IPFbg into synaptosomes on glutamate release. As shown in Fig. 3(b Fig. 4(a) (Fig. 4b) . In order to con®rm that IPF was indeed introduced into synaptosomes by freeze/thaw treatment, the synaptosomal cytosol fraction was assayed for IPF by Western blot with anti-IPF N-terminal peptide antiserum. As shown in Fig. 4(c) , the intrasynaptosomal content of IPF was increased as a function of the amount of IPF present in the medium during the freeze/thaw period. In the absence of added IPF, IPF was hardly detected. This could be due to its leakage into the larger volume of the medium, as a result of the freeze/thawinduced permeabilization and resealing. These results support the notion that an increase in IPF within the synaptosome leads to a decrease in the amount of [ 3 H] glutamate released by the exocytotic mechanism.
Concentration-dependence of inhibition by IPF

Fodrin introduction into synaptosomes does not alter [ 3 H]glutamate release
Sequence analysis of IPF suggests that IPF is produced by at least two steps of proteolytic cleavage, from the a subunit of fodrin, a major cytoskeletal protein (O È zkan et al. 1997) . IPF thus formed has the N-terminal sequence distinct from that of a-fodrin; the C-terminal sequence of IPF is yet to be determined. In contrast to IPF, neither isolated fodrin nor afodrin exhibited inhibitory activity in glutamate uptake into isolated synaptic vesicles (data not shown). Here, isolated fodrin was incorporated into synaptosomes by the same procedure used for introduction of IPF into synaptosomes. Its effect on [ 3 H]glutamate release from these synaptosomes was then compared with the effect of incorporation of IPF determined in parallel experiments. As shown in Fig. 5(a) , introduction of isolated fodrin had no effect on [ 3 H]glutamate release even at the highest concentration tested (85 nm), in contrast to IPFa, which exhibited substantial inhibition at this concentration (see Fig. 4a ). At 126 nm, IPFa and IPFb caused similar degrees of inhibition in the experiments shown in Figs 4(a) and 5(a). Moreover, introduction of isolated a-fodrin (at 293 nm, calculated based upon the molecular weight of 284 000) into synaptosomes led to no inhibition of glutamate release (data not shown). Fig. 5(b) indicates that fodrin is incorporated into synaptosomes in a concentration-dependent manner. Fodrin's inability to affect [ 3 H] glutamate release is therefore not due to its failure to enter the synaptosome. The two prominent bands above the a-fodrin band probably represent aggregated forms of a-fodrin. Synaptosomes were ®rst subjected to permeabilization (without IPF), resealing, washing, incubation at 308C for 10 min, and two ®nal washings, and suspended in BSS, as described in Materials and methods. IPFa was then added to give a ®nal concentration of 126 nM (after resealing). Aliquots (250 mL) were assayed for [ Extrasynaptosomal IPF has no effect on [ 3 H] glutamate release In order to con®rm that IPF affects glutamate release intrasynaptosomally as opposed to extrasynaptosomally, synaptosomes were ®rst permeabilized, resealed, washed and then subjected to glutamate release in the presence or absence of IPF (126 nm) under the four conditions described in the Fig. 4 legend. Under these conditions, IPF had no effect on glutamate release from synaptosomes (Fig. 6a) . Fig. 6(b) shows that IPF was hardly entrapped into synaptosomes when added after synaptosomes had been resealed. These results indicate that IPF does not act from the exterior of the synaptosome but rather functions within the synaptosome.
Neurotransmitter speci®city of IPF action IPF has been shown to inhibit not only accumulation of glutamate into isolated synaptic vesicles but also accumulation of GABA (O È zkan et al. 1997) , suggesting that IPF may not speci®cally regulate glutamate storage in vivo. In order to gain insight into this matter, we have determined the effect of IPF incorporation into synaptosomes on the subsequent exocytotic release of GABA and serotonin (a representative monoamine neurotransmitter). As shown in Fig. 7 results raise the possibility that IPF could affect vesicular storage of multiple neurotransmitters in vivo.
Subcellular distribution of IPF
In order for IPF to play a physiological role as a vesicular neurotransmitter storage inhibitor, IPF would have to occur in the nerve ending. To address this issue, a freshly prepared rat brain homogenate was subfractionated and each subcellular fraction analyzed for IPF. Fig. 8 shows that IPF (M r 138 000) is present in the rapidly prepared homogenate, indicating that it occurs in the intact cell; this rules out the possibility that IPF is a puri®cation artifact. Of interest, the Figure also shows that IPF, of all the subcellular fractions tested, is most concentrated in the synaptosomal cytosol fraction. It was hardly detected in the nuclear fraction and the plasma membrane/mitochondrian/myelin fraction derived from the P2 fraction. However, signi®cant amounts of IPF were found in the puri®ed synaptic vesicle fraction (Fig. 8, lane 11) ; this is consistent with high af®nity of IPF for synaptic vesicles, as judged by its high potency in vesicular glutamate/GABA uptake inhibition (O È zkan et al. 1997) .
Discussion
Neural communication is thought to be most effectively modulated at the level of synaptic transmission. A variety of evidence indicates that there are diverse modes of presynaptic as well as postsynaptic modulation. Presynaptic regulation results in an alteration in the amount of neurotransmitter released from the nerve terminal per given period of time. This regulation can be achieved by modulating (a) voltage-dependent calcium channels (Dolphin 1990; Miller 1990; Baskys and Malenka 1991; Barrie and Nicholls 1993; Colmers and Bleakman 1994; Dittman and Regehr 1996; Stefani et al. 1996; Takahashi et al. 1996) ; (b) potassium channels (Kandel and Schwartz 1992; Augustine 1990; Herrero et al. 1992; Robitaille and Charlton 1992) ; (c) the Na 1 /Ca 21 exchanger (Gleason et al. 1994; Bouron and Reuter 1996) ; (d) the nicotinic acetylcholine receptor non-selective cation channel (McGehee et al. 1995) ; (e) the cyclic nucleotide-gated channel (Rieke and Schwartz 1994; Savchenko et al. 1997) ; (f) transition from the neurotransmitter pool reserve state to the ready-release state, or priming process (Bittner and Holz 1992; Greengard et al. 1993; Neher and Zucker 1993; Smith et al. 1998) ; and (g) the ®nal exocytotic release process (Prince and Stevens 1992; Scholz and Miller 1992; Silinsky and Solsona 1992; Chavez-Noriega and Stevens 1994; Capogna et al. 1996; Dittman and Regehr 1996; Trudeau et al. 1996; Kinney et al. 1998) , not to mention neurotransmitter synthesis. In addition, it is conceivable that the amount of neurotransmitter to be released could be altered by varying the synaptic vesicleõ Âs transmitter storage activity or capacity. Relatively little attention had been paid to this aspect of the endogenous regulation of neurotransmission.
Observations presented in this communication provide evidence that endogenous substances in the nerve terminal, such as IPF, might play a role in regulating neurotransmitter release by inhibiting neurotransmitter accumulation into synaptic vesicles. We have previously provided evidence that isolated IPF potently inhibits glutamate uptake into isolated synaptic vesicles; IPF is devoid of inhibitory activity toward ATP-independent glutamate uptake as well as toward Na The potency of IPF in release (IC 50 ,84 nm) was found to be in general agreement with that in glutamate uptake into isolated synaptic vesicles (IC 50 26 nm). This would argue for the notion that the IPF-induced decrease in the amount of exocytotically released glutamate is mediated by inhibition by IPF of vesicular glutamate uptake. IPF does not bear the actin-binding domain of fodrin; IPF is within the N-terminal half of a-fodrin (O È zkan et al. 1997) and actin binds to the N-terminal region of b-fodrin (Karinch et al. 1990 ). This rules out the possibility that the inhibitory effect of IPF on release is mediated by an alteration in the interaction with actin. The role of actin in mediating IPFinduced inhibition is also ruled out since incorporation into synaptosomes of puri®ed fodrin, which is capable of interacting with actin (Goodman et al. 1995) , failed to affect [ 3 H] glutamate release. However, alternative possibilities, such as the effect on other vesicle priming steps and the ®nal release step, in addition to or instead of vesicular storage of transmitters, are not ruled out at present. It also remains to be determined whether synaptic vesicle glutamate content is reduced within the IPF-containing synaptosomes.
Since discovery of the miniature endplate potential at the neuromuscular junction and formulation of the quantal release theory (Fatt and Katz 1952; Del Castillo and Katz 1954) , much study had focused on alteration of quantal content (quantal number) and its mechanism. We postulate that IPF might function as an endogenous regulator of this quantal release. Recent evidence points to the notion that quantal size is variable and that vesicular neurotransmitter content can be altered (Doherty et al. 1984; Whitton et al. 1986; Bekkers et al. 1990; Van der Kloot 1991; Stevens 1993) . At the neuromuscular synapse, quantal size can be changed under certain conditions, such as prolonged stimulation, an increase in intracellular Ca 21 , exposure to acetylcholine agonists and hypertonic solutions, as well as exposure to vesamicol, a potent inhibitor of the vesicular acetylcholine transporter. More recently, Brailoiu and Van der Kloot (1996) have shown that acetylcholine quantal size is reduced by introduction of acetylcholine esterase or the choline acetyltransferase inhibitor bromoacetylcholine into motor nerve endings. In the central nervous system, Pothos et al. (1998) have provided direct evidence that the number of dopamine molecules per releasable quantum from mid-brain dopaminergic neurons is increased by exposure either to a glial-derived neurotrophic factor (GDNF) or to the dopamine precursor l-dihydroxyphenylalanine (l-DOPA).
IPF may represent the ®rst example of an endogenous substance which can intracellularly control quantal size of amino acid neurotransmitters, not by regulating their synthesis, but by modulating their uptake into synaptic vesicles. Controlling quantal size may be important in preventing neurotransmitter over¯ow onto neighboring synapses and/or abnormally prolonged activation of postsynaptic receptors, as well as in modulating build-up of the threshold potential required for triggering the action potential.
Evidence presented here indicates that, under in vitro conditions, IPF introduced into the synaptosome is capable of decreasing the amount of exocytotically released glutamate, GABA and serotonin. This suggests that IPF can inhibit uptake of monoamine transmitters, as well as of glutamate and GABA, into synaptic vesicles within synaptosomes. This is somewhat at odds with previous work which demonstrated that IPF has little effect on catecholamine uptake into dense-core granules isolated from chromaf®n cells (O È zkan et al. 1997) . Amino acid neurotransmitters are stored in clear, small synaptic vesicles, whereas monoamine transmitters, including serotonin, are stored in both clear vesicles and dense-core vesicles (Maley et al. 1990; Bruns and Jahn 1995; Johnson and Yee 1995) . These observations, taken together, raise the possibility that several, if not all, types of clear vesicles may share a common IPF binding site or protein, de®cient in dense-core vesicles. Consistent with the proposed role of IPF as a presynaptic regulator of exocytotic glutamate release, speci®c content of IPF was found to be highest in the synaptic vesicle fraction of all brain subcellular fractions tested (Fig. 8) . Whether IPF regulation occurs with multiple types of neurotransmitters in vivo is not known. It would depend upon whether IPF is present, for example, in the glutamatergic, GABAergic, or monoaminergic nerve terminal.
IPF is structurally related to, but functionally distinct from, the a subunit of the major cytoskeletal protein fodrin. In contrast to IPF, neither isolated fodrin nor its a subunit affects vesicular glutamate uptake or glutamate release. IPF differs from a-fodrin in its N-terminal sequence and presumably in its C-terminal sequence as well (O È zkan et al. 1997) . Based upon amino acid sequence analysis, it is thought that IPF is produced from a-fodrin via two or more steps of cleavage. However, how IPF is produced and its activity regulated remain to be elucidated.
